Výsledky vyhledávání

Elektronická kniha

Immunoassay : A Survey of Patents, Patent Applications and Other Literature 1980-1991

Autor: B. Salomons, J. Sigmond, M. Terpstra

This book presents the results of a comprehensive study of literature on patents, patent applications and other literature, such as journal articles. The survey covers literature published from the United States, Japan and Western Europe between Janu

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer

Autor: Giuseppe Giaccone, Clemens M F Dirven, J.C.A. Baayen, C.J. van Groeningen, K. van der Born, G.J. Peters, J. Sigmond, S.M. de Lange, Richard J. Honeywell, Tjeerd J. Postma, Andre M. Bergman, A.C. Laan

Publikováno v: Sigmond, J, Honeywell, R J, Postma, T J, Dirven, C M, de Lange, S M, van der Born, K, Laan, A, Baayen, J C, van Groeningen, C J, Bergman, A M, Giaccone, G & Peters, G J 2009, ' Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer ', Annals of Oncology, vol. 20, no. 1, pp. 182-187 . https://doi.org/10.1093/annonc/mdn543
Annals of Oncology, 20(1), 182-187. Elsevier Ltd.
Annals of Oncology, 20(1), 182-187. Oxford University Press

Glioblastoma multiforme (GBM), the most frequent malignant brain tumor, has a poor prognosis, but is relatively sensitive to radiation. Both gemcitabine and its metabolite difluorodeoxyuridine (dFdU) are potent radiosensitizers. The aim of this phase

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36b798c2a7b9ecb35945758e6851be2e
https://doi.org/10.1093/annonc/mdn543

Zobrazit plný text záznamu

Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells

Autor: G.J. Peters, C Tekle, J. Sigmond, Elisa Giovannetti, Kees Smid, Jeremy R. Graff

Publikováno v: Tekle, C, Giovannetti, E, Sigmond, J, Graff, J R, Smid, K & Peters, G J 2008, ' Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells ', British Journal of Cancer, vol. 99, no. 5, pp. 750-759 . https://doi.org/10.1038/sj.bjc.6604566
British Journal of Cancer, 99(5), 750-759. Nature Publishing Group
British Journal of Cancer

Conventional regimens have limited impact against non-small cell lung cancer (NSCLC). Current research is focusing on multiple pathways as potential targets, and this study investigated molecular mechanisms underlying the combination of the PKC beta

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e299d819f507482f6f62a6b2ecd083d3
https://doi.org/10.1038/sj.bjc.6604566

Zobrazit plný text záznamu

Enhanced activity of deoxycytidine kinase after pulsed low dose rate and single dose gamma irradiation

Autor: Nicolaas A. P. Franken, Jaap Haveman, G.J. Peters, C. van Bree, N. Castro Kreder, J. Sigmond, Willem J.P Loves

Publikováno v: Nucleosides, nucleotides & nucleic acids, 25(9-11), 1177-1180. Marcel Dekker Inc.

In both pulsed low dose rate (LDR) and single high dose radiation schedules, gemcitabine pretreatment sensitizes tumor cells to radiation. These radiosensitizing effects could be the result of decreased DNA repair. In this study, the effect of irradi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e10080f68b6357e9be161497a984b8ae
https://doi.org/10.1080/15257770600894394

Zobrazit plný text záznamu

Quantitative Real Time PCR of Deoxycytidine Kinase mRNA by Light Cycler PCR; in Relation to Enzyme Activity

Autor: Judith R. Kroep, Godefridus J. Peters, Willem J.P Loves, J. Sigmond

Publikováno v: Nucleosides, Nucleotides and Nucleic Acids. 23:1347-1350

Deoxycytidine kinase (dCK) is essential for the phosphorylation of several deoxyribonucleosides and various analogues such as gemcitabine (2′,2′‐difluorodeoxycytidine). We developed and optimized a sensitive real time Light Cycler (LC) PCR assa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35b74dadf494c77bf14971a78cd7e525
https://doi.org/10.1081/ncn-200027611

Zobrazit plný text záznamu

Plný text ve formátu HTML

Effect of staurosporine and ucn-01 on gemcitabine cytotoxicity in relation to cell cycle effects and p53 status

Autor: J. Sigmond, J. A. E. Kamphuis, G.J. Peters, Andre M. Bergman, L.G. Leon

Publikováno v: Sigmond, J, Leon, L G, Kamphuis, J A E, Bergman, A M & Peters, G J 2012, ' Effect of staurosporine and ucn-01 on gemcitabine cytotoxicity in relation to cell cycle effects and p53 status ', Journal of Cancer Therapeutics & Research, vol. 1, 29 . https://doi.org/10.7243/2049-7962-1-29#sthash.1rop7IZX.dpuf
Journal of Cancer Therapeutics & Research, 1:29

Gemcitabine (dFdC) is an anti-cancer agent that is affected by cell cycle modulation. Staurosporine and 7-hydroxystaurosporine (UCN-01) are potent protein kinase C (PKC) inhibitors as well as inhibitors of cyclin dependent

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::837c1ccfce9653e9e3795de94a7d76c2
https://research.vumc.nl/en/publications/1ccb4f29-969c-4790-84a9-5953dbff4199

Zobrazit plný text záznamu

Staurosporine increases toxicity of gemcitabine in non-small cell lung cancer cells: role of protein kinase C, deoxycytidine kinase and ribonucleotide reductase

Autor: J. Sigmond, Godefridus J. Peters, Willem J.P Loves, Eveline K. Hoebe, Andries M. Bergman, Leticia G. Leon

Publikováno v: Sigmond, J, Bergman, A M, Leon, L G, Loves, W J P, Hoebe, E K & Peters, G J 2010, ' Staurosporine increases toxicity of gemcitabine in non-small cell lung cancer cells: role of protein kinase C, deoxycytidine kinase and ribonucleotide reductase ', Anti-Cancer Drugs, vol. 21, no. 6, pp. 591-599 . https://doi.org/10.1097/CAD.0b013e32833a3543
Anti-cancer drugs, 21(6), 591-599. Lippincott Williams and Wilkins
Anti-Cancer Drugs, 21(6), 591-599. Lippincott Williams and Wilkins

Gemcitabine, a deoxycytidine analog, active against non-small cell lung cancer, is phosphorylated by deoxycytidine kinase (dCK) to active nucleotides. Earlier, we found increased sensitivity to gemcitabine in P-glycoprotein (SW-2R160) and multidrug r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e16446e55f139f3b2f54ef087244227d
https://pubmed.ncbi.nlm.nih.gov/20436341

Zobrazit plný text záznamu

Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC)

Autor: Richard J. Honeywell, Axel R. Hanauske, Godefridus J. Peters, Elisa Giovannetti, Giuseppe Giaccone, J. Sigmond, Bart C. Kuenen, Christina Tekle

Publikováno v: Giovannetti, E, Honeywell, R J, Hanauske, A R, Tekle, C, Kuenen, B, Sigmond, J, Giaccone, G & Peters, G J 2010, ' Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC) ', Current Drug Targets, vol. 11, no. 1, pp. 12-28 . https://doi.org/10.2174/138945010790031009
Current Drug Targets, 11(1), 12-28. Bentham Science Publishers B.V.

Conventional regimens have limited impact against NSCLC. Current research is focusing on multiple pathways as potential targets, and this review describes pharmacological aspects underlying the combination of the PKCbeta-inhibitor enzastaurin with th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2d9b2d96f88d91013a6785635525f6e
https://research.vumc.nl/en/publications/fc0ee58c-230b-49f8-a94e-df9de4fd6c5a

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání